Test: 25-hydroxyvitamin D (25-D)

Also known as 25-hydroxyvitamin D, 25-DThe vitamin D metabolite widely (and erroneously) considered best indicator of vitamin D "deficiency." Inactivates the Vitamin D Nuclear Receptor. Produced by hydroxylation of vitamin D3 in the liver. is the inactive form of vitamin D. Like 1,25-DPrimary biologically active vitamin D hormone. Activates the vitamin D nuclear receptor. Produced by hydroxylation of 25-D. Also known as 1,25-dihydroxycholecalciferol, 1,25-hydroxyvitamin D and calcitirol., 25-D has an affinity for the Vitamin D ReceptorA nuclear receptor located throughout the body that plays a key role in the innate immune response. (VDRThe Vitamin D Receptor. A nuclear receptor located throughout the body that plays a key role in the innate immune response.), but unlike 1,25-D, it inactivates the Receptor.

When researchers or journalists talk about vitamin D deficiency, they are invariably talking about low levels of 25-D as opposed to 1,25-D. According to the Marshall PathogenesisA description for how chronic inflammatory diseases originate and develop., the body purposefully downregulates levels of 25-D so as to upregulate activity of the VDR.

As the vitamin D metabolite calculator states, any 25-D of 20 ng/ml or higher is immunosuppressive and should be countered by restricting consumption of vitamin D.

If a patient's 25-D is low enough, they typically can enjoy an infrequent splurge of food containing vitamin D.

When to test 25-D

Patients should ask their physicians to order a baseline 25-D test prior to beginning olmesartan (Benicar)Medication taken regularly by patients on the Marshall Protocol for its ability to activate the Vitamin D Receptor.. Marshall ProtocolA curative medical treatment for chronic inflammatory disease. Based on the Marshall Pathogenesis. patients whose 25-D is above 20 ng/ml should continue to be tested every three months. This allows the doctor and the patient to anticipate a possible increase in immunopathologyA temporary increase in disease symptoms experienced by Marshall Protocol patients that results from the release of cytokines and endotoxins as disease-causing bacteria are killed. (IP), which corresponds to a 25-D level of 20 ng/ml.

Intermittent testing (once every six months or longer) can continue thereafter to verify a patient is continuing to successfully avoid food containing vitamin D.

How to test 25-D

MP patients getting their 25-D levels tested should ensure the relevant instructions are closely followed.

Interpreting a 25-D test

Contextual interpretation of a patient's 25-D and 1,25-D results are available using the vitamin D metabolite calculator.

A patient may get a test result, breaking down their 25-D into two different kinds:

  • 25 D3 – synthesized on human skin when exposed to light; enters the body when a person consumes animal products that contain vitamin D
  • 25 D2 – enters the body when a person consumes plants or fungi that contain vitamin D

Units of measurement

On the Marshall Protocol study site, 25-D levels are typically discussed using ng/ml units rather than pmol/L. The ratio between the two units is: 1 ng/ml = 2.5 nmol/L. To convert nmol/L into ng/ml, multiply by 0.40, as you see in this example:

60 nmol/L * 0.40 = 24 ng/mL

This is also done automatically with the vitamin D metabolite calculator.

Diseases with a low 25-D

Lower than normal levels of 25-D have been independently associated both with all-cause mortality1) and dozens of chronic inflammatory diseases ranging from alcoholism 2) to allergies3) to prostate cancer.4)

For this reason, low levels of 25-D can be used (in countries that supplement) as a proxy for chronic disease.

Not a simple fat-soluble vitamin

A recent analysis concluded that surrogate markers for vitamin D exposure including age, vitamin D intake, supplement use, latitude, etc. taken together, could explain only 21 percent of the variation in vitamin D levels between people.5)

As a 2010 Tasmanian study demonstrated, body fat is not simply a passive reservoir for 25-D. The study showed that the associations between body adiposity (fat) measures and change in 25-D completely disappeared after adjustment for leptin (an appetite hormone), diminished after adjustment for IL-6 (a cytokineAny of various protein molecules secreted by cells of the immune system that serve to regulate the immune system.), but remained unchanged after adjustment for total cholesterol/HDL ratio. Therefore, in addition to season and sun exposure, 25-D levels appear to be determined by metabolic and, to a lesser extent, inflammatory factors, and these appear to mediate the effects of adiposity (body fat) on change in 25-D.6)

Reference range for 25-D

The question of what should be the appropriate reference range for vitamin D involves several issues.

Healthy people who do not supplement have naturally low levels of 25-D

Observational studies show that populations which avoid vitamin D consumption have naturally low levels of 25-D and remain healthy with such levels.

  • A study which tested the level of 25-D in 90 “healthy, ambulatory Chilean women” showed that 27% of the premenopausal and 60% of the postmenopausal women had 25-D levels under 20 ng/ml. 7)
  • A study on healthy Bangladeshi women found that approximately 80% of the women had a level of 25-D under 16 ng/ml. 8)
  • In a 1992 study, healthy full-term infants from China had serum concentrations of 25-D ranging from an average of 5 ng/ml to 14 ng/ml. 9)

Patients with chronic diseases naturally downregulate levels of 25-D

There are several molecular pathways activate in chronic inflammatory disease, which cause levels of 25-D to fall to “deficient” levels. (For example, Reid et al. showed that blood levels 25-D decrease after an inflammatory insult such elective knee arthroplasty.10)) It is in the interest of such patients to have low levels of 25-D, as low levels increase the activity of the VDR – a receptor which, when activated, plays a key role in innate immune function.

Under such circumstances, a patient who supplements with vitamin D may see a rise in 25-D. However, the increase in serum levels of 25-D would not be quite as high as it otherwise would be in a healthy person.

In other words, the body's enzymatic regulation of the D metabolites can be forcefully overridden by heavy dietary and supplemental intake of D precursors.

The explanation presented here for why 25-D is low in patients with chronic disease runs counter to the more commonly given but incorrect description, namely that patients “use up” vitamin D as they would a true vitamin.

Establishing a reference range

The high rate of chronic disease and the presence of vitamin D supplementation has led to a misunderstanding about what constitutes a healthy or normal range for vitamin D. Laboratories establish a “normal” range for the D metabolites results based on studies purportedly looking at the average of all the “healthy” persons who are tested. Clinicians have yet to recognize the reason for low levels of 25-D and usually recommend supplementation with vitamin D. Therefore, lab ranges for 25-D may be skewed higher and higher by the increasingly prevalent use of dietary supplementation.

Vitamin D values may take years to come into as normal range. Four patients who poisoned themselves with vitamin D supplements were followed over a period of several years of vitamin D near abstinence. The authors describe the rate of decrease as 10.7 ± 3.0 nmol/L per month. Note the y-axis: even after two, three or more years of abstinence, none of the patients have levels of vitamin D that ceased to be immunosuppressive.

The therapeutic range for Marshall Protocol patients is 11 ng/ml or lower. MP patients often have a 25-D below the detectable limit of 5-7 ng/ml.

Expected rate of decline in 25-D

The rate at which 25-D declines in Marshall Protocol patients tends to vary. Adams et al. (right) showed that the rate of at which 25-D declined among people who taken high amounts of vitamin D supplements and subsequently abstained from supplements is approximately 10.7 ± 3.0 nmol/L per month.11)

Recalcitrant 25-D – why 25-D could remain high over the course of several years

Sometimes, a patient will be on the MP for 18 months or more, and their 25-D will still be elevated above the therapeutic range – that is, greater than 20 ng/ml. Sometimes a patient has been mistakenly consuming food or supplements containing vitamin D. This explanation must never be overlooked.

The best way to check if a patient is taking vitamin D is to carefully review the possible sources of vitamin D including supplements. Many foods and supplements contain unlisted amounts of vitamin D. Patients can try varying their diet and re-testing themselves to see if this changes their measurable level of 25-D.

However, even patients avoiding supplemental vitamin D and without significant body fat – where vitamin D is supposedly stored – can have high levels of 25-D.

Why did her 25-D take so long to drop, especially when she has so little body-fat for “storage”, while obese individual's 25-D can drop quickly? I would postulate that it is because 25-D is not stored, it is metabolized, and the metabolism is out-of-whack.

Trevor Marshall, PhD

Factors that may contribute to unexpected 25-D

Here are several factors may play a role in contributing to unexpected levels of 25-D:

I have found elevated levels of 25-D in compliant patients. It is usually due to an intestinal Candida overgrowth or biofilm A structured community of microorganisms encapsulated within a self-developed protective matrix and living together.. I have found treating with Nystatin, a non-absorbable antifungal azole effective in reducing Candida load and with resultant marked reduction in 25-D levels, often within 1 to 2 months.

Greg Blaney, M.D.

As I have indicated in the past I have seen marked changes in vitamin D serum metabolite measurements including 25-D levels that had nothing to do with diet or light exposure. I have also witnessed immunopathology is patients with serum 25-D levels as high as 30 ng/ml. So obviously what is happening intracellularly does not always reflect in extracellular markers.

Greg Blaney, M.D.

25-D after recovery

Endogenous 25-D production will not start to rise until the bacteria have been largely eliminated, which will be in the final few years of MP immunopathology. A healthy 25-D level varies widely, with 25-D being manufactured as the body needs it, and with the maximum level in a healthy person being about 18ng/ml.

Trevor Marshall, PhD

Patients experiences

My feeling worse corresponded to dropping levels of 25-D. Although our “therapeutic range” is <12ng/ml, my own experience of going from 12ish to 4ng fairly rapidly was feeling considerably worse pretty quickly. My own apparent deterioration seems to have begun to reverse over the subsequent 8-9 months. Everyone's different, but perhaps you'll also find this to be the case. So hang in there, and in the meantime do what you can to keep things tolerable.

pgeek, MarshallProtocol.com

Read more

===== Notes and comments =====

“Above 21 nanograms per milliliters, the data suggest that the protective effect appears to wear off”

Question, when both D2 & D3 are measured, is the D3 result alone considered the 25D value?

Also, what about claims that Quest's new testing is creating false “high” results…

It seems that there are *different* *methods* used for VitD testing (the 25OHD aka 25 hydroxyvitamin D).

One method, “RIA,” was typically used in the studies that have served to tell us what “levels” of VitD are better for us.

There's another method, “LIASON,” that gives results very similar to those of RIA, so it's fine to compare LIASON test results with recommendations based on RIA test results. (It seems Lab Corp uses LIASON.)

However, there's also the (newer) “LC-MS/MS” method, which yields results that are *not* comparable with the others; they're typically (always?) lower! (They also can split out D2 and D3 which can be a good thing it seems.) Quest uses this method.

Apparently, Mayo Clinic and ZRT also use LC-MS/MS, but it seems they “calibrate” results so that they are comparable to those from the RIA or LIASON methods.

According to Dr Cannell at vitamindcouncil.org, as of 1/9/09 Quest was not calibrating their results to make them comparable to RIA. He recommends dividing Quest result by 1.3. A Quest 47 would become a 36!

But wait—Dr Mercola says to multiply a Quest result by 0.6, making a Quest 47 only 28!

A ZRT Labs document claims the average RIA measure is 20-30% lower than a LC-MS/MS measure of same sample (making a Quest 47 be in the 33-38 range).

I think it makes sense to bypass Quest and any who provide non-comparable results—unless a physician wants the D2 & D3 split out and/or can convert the values! Then, whatever the Lab we use, we need to find out whether or not the results are comparable with the RIA method. (And if not, find out if the lab will provide a “converted” value that is comparable — or “convert” your target so you know when you're there.) Then, stick with one lab (for simplicity).

I'm really surprised that this kind of thing is going on!

Zeta brought the Cannell/Quest info to a discussion here https://www.inspire.com/groups/national-osteoporosis-foundation/discussion/v itamin-d-testing-problem/ I didn't read it closely then because I don't use Quest.

I'm going to find out about the method used by my Lab, and Jacqueline I really appreciate that you brought this topic up again!

(Also on a Quest site it says “fasting is preferred” for this test. Hmmm…)

Here are some of the links I checked:

https://laboratory-manager.advanceweb.com/Editorial/Content/Editorial.aspx?C C=191618



https://www.curezone.com/forums/fm.asp?i=1345487 (or perhaps see https://articles.mercola.com/sites/articles/archive/2009/01/20/the-overwhelm ing-evidence-that-sunlight-fights-cancer.aspx )


Contribution of Adipose Tissue to Plasma 25-Hydroxyvitamin D Concentrations During Weight Loss Following Gastric Bypass Surgery.

Lin E, Armstrong-Moore D, Liang Z, Sweeney JF, Torres WE, Ziegler TR,Tangpricha V, Gletsu-Miller N Obesity (Silver Spring) Oct 2010; Full text via publisher | Download citation Affiliation Department of Surgery, Emory University School of Medicine, Atlanta, Georgia, USA. Abstract Roux-en-y gastric bypass (RYGB) surgery is associated with dramatic improvements in obesity-related comorbidity, but also with nutritional deficiencies. Vitamin D concentrations are depressed in the severely obese, but the impact of weight loss via RYGB is unknown. We determined associations between adiposity and systemic 25-hydroxyvitamin D (25(OH)D) during weight loss and the immediate and longer-term effects of RYGB. Plasma 25(OH)D concentrations and fat mass (FAT) were determined by immunoassay and air displacement plethysmography, respectively, at 0 (before RYGB surgery), and at 1, 6, and 24 months in severely obese white and African American (AA) women (n = 20). Decreases in adiposity were observed at 1, 6, and 24 months following RYGB (P < 0.05). Plasma 25(OH)D concentrations increased at 1 month (P = 0.004); a decreasing trend occurred over the remainder months after surgery (P = 0.02). Despite temporary improvement in vitamin D status, a high prevalence of vitamin D insufficiency was observed (76, 71, 67, and 82%, at baseline, 1, 6, and 24 months, respectively), and plasma 25(OH)D concentrations were lower in AA compared to white patients (P < 0.05). Strong positive baseline and 1 month cross-sectional correlations between FAT and plasma 25(OH)D were observed, which remained after adjustment for age and race subgroup (β = 0.76 and 0.61, respectively, P = 0.02). In conclusion, 25(OH)D concentrations increased temporarily and then decreased during the 24 months following RYGB. The acute increase and the positive associations observed between adipose tissue mass and systemic 25(OH)D concentrations suggest storage in adipose tissue and release during weight loss


The study discussed here: Tea and coffee consumption in relation to vitamin D and calcium levels in Saudi adolescents provides additional evidence that non-supplemented populations have low 25D. 330 Saudi adolescents with average 25D levels of 8-10ng/mL. ===== References =====

Melamed ML, Michos ED, Post W, Astor B. 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med. 2008 Aug 11;168(15):1629-37. doi: 10.1001/archinte.168.15.1629.
[PMID: 18695076] [PMCID: 2677029] [DOI: 10.1001/archinte.168.15.1629]
Schneider B, Weber B, Frensch A, Stein J, Fritz J. Vitamin D in schizophrenia, major depression and alcoholism. J Neural Transm (Vienna). 2000;107(7):839-42. doi: 10.1007/s007020070063.
[PMID: 11005548] [DOI: 10.1007/s007020070063]
Hyppönen E, Berry DJ, Wjst M, Power C. Serum 25-hydroxyvitamin D and IgE - a significant but nonlinear relationship. Allergy. 2009 Apr;64(4):613-620. doi: 10.1111/j.1398-9995.2008.01865.x.
[PMID: 19154546] [DOI: 10.1111/j.1398-9995.2008.01865.x]
Lou Y, Qiao S, Talonpoika R, Syvälä H, Tuohimaa P. The role of Vitamin D3 metabolism in prostate cancer. J Steroid Biochem Mol Biol. 2004 Nov;92(4):317-25. doi: 10.1016/j.jsbmb.2004.10.007. Epub 2004 Dec 19.
[PMID: 15663995] [DOI: 10.1016/j.jsbmb.2004.10.007]
Millen AE, Wactawski-Wende J, Pettinger M, Melamed ML, Tylavsky FA, Liu S, Robbins J, LaCroix AZ, LeBoff MS, Jackson RD. Predictors of serum 25-hydroxyvitamin D concentrations among postmenopausal women: the Women's Health Initiative Calcium plus Vitamin D clinical trial. Am J Clin Nutr. 2010 May;91(5):1324-35. doi: 10.3945/ajcn.2009.28908. Epub 2010 Mar 10.
[PMID: 20219959] [PMCID: 2854906] [DOI: 10.3945/ajcn.2009.28908]
Ding C, Parameswaran V, Blizzard L, Burgess J, Jones G. Not a simple fat-soluble vitamin: Changes in serum 25-(OH)D levels are predicted by adiposity and adipocytokines in older adults. J Intern Med. 2010 Nov;268(5):501-10. doi: 10.1111/j.1365-2796.2010.02267.x.
[PMID: 20804516] [DOI: 10.1111/j.1365-2796.2010.02267.x]
González G, Alvarado JN, Rojas A, Navarrete C, Velásquez CG, Arteaga E. High prevalence of vitamin D deficiency in Chilean healthy postmenopausal women with normal sun exposure: additional evidence for a worldwide concern. Menopause. 2007 May-Jun;14(3 Pt 1):455-61. doi: 10.1097/GME.0b013e31802c54c0.
[PMID: 17290161] [DOI: 10.1097/GME.0b013e31802c54c0]
Islam MZ, Akhtaruzzaman M, Lamberg-Allardt C. Hypovitaminosis D is common in both veiled and nonveiled Bangladeshi women. Asia Pac J Clin Nutr. 2006;15(1):81-7.
[PMID: 16500882]
Specker BL, Ho ML, Oestreich A, Yin TA, Shui QM, Chen XC, Tsang RC. Prospective study of vitamin D supplementation and rickets in China. J Pediatr. 1992 May;120(5):733-9. doi: 10.1016/s0022-3476(05)80236-7.
[PMID: 1578308] [DOI: 10.1016/s0022-3476(05)80236-7]
Reid D, Toole BJ, Knox S, Talwar D, Harten J, O'Reilly DSJ, Blackwell S, Kinsella J, McMillan DC, Wallace AM. The relation between acute changes in the systemic inflammatory response and plasma 25-hydroxyvitamin D concentrations after elective knee arthroplasty. Am J Clin Nutr. 2011 May;93(5):1006-11. doi: 10.3945/ajcn.110.008490. Epub 2011 Mar 16.
[PMID: 21411617] [DOI: 10.3945/ajcn.110.008490]
Adams JS, Lee G. Gains in bone mineral density with resolution of vitamin D intoxication. Ann Intern Med. 1997 Aug 1;127(3):203-6. doi: 10.7326/0003-4819-127-3-199708010-00004.
[PMID: 9245225] [DOI: 10.7326/0003-4819-127-3-199708010-00004]
Katsuki H, Bloch K. Studies on the biosynthesis of ergosterol in yeast. Formation of methylated intermediates. J Biol Chem. 1967 Jan 25;242(2):222-7.
[PMID: 6016607]
Parks LW, Casey WM. Physiological implications of sterol biosynthesis in yeast. Annu Rev Microbiol. 1995;49:95-116. doi: 10.1146/annurev.mi.49.100195.000523.
[PMID: 8561481] [DOI: 10.1146/annurev.mi.49.100195.000523]
home/tests/25d.txt · Last modified: 09.14.2022 by
© 2015, Autoimmunity Research Foundation. All Rights Reserved.